BeiGene's RAF dimer inhibitor, lifirafenib (BGB-283), will be evaluated in combination with SpringWorks Therapeutics’ investigational MEK inhibitor, PD-0325901, in a phase 1b clinical trial in patients with advanced solid tumors.
Gilead Sciences and Galapagos’ filgotinib has reached its primary efficacy endpoint in active ankylosing spondylitis study (AS).
Biothera Pharmaceuticals has entred into a clinical collaboration with AstraZeneca to evaluate whether the combination of Biothera’s Imprime PGG and AstraZeneca’s durvalumab (IMFINZI) can decrease tumor volume in patients with primary untreated locally advanced head and neck cancer prior to surgical resection.
AstraZeneca’s lupus drug anifrolumab has failed to meet the primary endpoint in the Tulip 1 phase III trial.
Pfizer said that it is terminating two ongoing trials - B5161002, a phase 2 safety and efficacy study and B5161004, an open-label extension study, which are assessing domagrozumab (PF-06252616) for the treatment of Duchenne muscular dystrophy (DMD).
Sonoma Pharmaceuticals has announced the results from a study, which assessed the use of its proprietary high-strength performance-stabilized HOCl (Hypochlorous Acid) in the management of acne vulgaris.
MGC Pharmaceuticals (MXC) has secured a key approval in Australia to launch a phase 2 trial to evaluate CogniCann, a medicinal cannabis compounded formulation, as a potential treatment of mild Dementia and Alzheimer’s.
AstraZeneca’ Bevespi Aerosphere (glycopyrronium/formoterol fumarate) has failed to demonstrate superiority against umeclidinium/vilanterol in treating patients with moderate to very severe chronic obstructive pulmonary disease (COPD) in the phase IIIb trial.
Pfizer and Astellas Pharma have announced amendments to the protocols for two registrational phase 3 trials, ARCHES and EMBARK, designed to evaluate the safety and efficacy of XTANDI (enzalutamide) in men with hormone-sensitive prostate cancer (HSPC).
Can-Fite BioPharma has enrolled and dosed the first patient in its phase 3 Comfort trial to evaluate its small orally bioavailable drug Piclidenoson (CF101) for the treatment of moderate-to-severe plaque psoriasis.
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.